Argenx
ARGX
#579
Rank
NZ$61.02 B
Marketcap
$998.00
Share price
0.77%
Change (1 day)
18.97%
Change (1 year)
Argenx is a Dutch company that develops antibody therapies to fight autoimmune diseases and cancer.

Argenx (ARGX) - Total debt

Total debt on the balance sheet as of June 2024 : NZ$56.86 Million

According to Argenx 's latest financial reports the company's total debt is NZ$56.86 Million. A companyโ€™s total debt is the sum of all current and non-current debts.

Argenx - Total debt on balance sheet (from 2017 to 2020)

Total debt by year

Year Total debt Change
2022-12-31NZ$19.57 M16.6%
2021-12-31NZ$16.78 M1.96%
2020-12-31NZ$16.46 M35.22%
2019-12-31NZ$12.17 M
2018-12-31N/A
2017-12-31N/A
2013-12-31N/A-100%
2012-12-31NZ$3.59 M-1.4%
2011-12-31NZ$3.64 M